血管紧张素-脑啡肽酶抑制在射血分数保留的心力衰竭中的应用
PARAGON-HF试验随机分配4822例NYHA II-IV级、射血分数≥45%、利钠肽升高且有结构性心脏病的心衰患者,接受沙库巴曲缬沙坦(目标剂量97mg沙库巴曲/103mg缬沙坦每日两次)或缬沙坦(目标剂量160mg每日两次)。主要复合终点(心衰总住院+心血管死亡)在沙库巴曲缬沙坦组526例患者共894次事件,缬沙坦组557例患者共1009次事件(率比0.87,95%CI 0.75-1.01,P=0.06),未达统计学显著。沙库巴曲缬沙坦组NYHA分级改善率更高(15.0% vs 12.6%,OR 1.45,95%CI 1.13-1.86),肾功能恶化更少(1.4% vs 2.7%,HR 0.50,95%CI 0.33-0.77),但低血压和血管性水肿发生率更高,高钾血症发生率更低。
要点
- 射血分数≥45%的心衰患者中,沙库巴曲缬沙坦对比缬沙坦未显著降低心衰总住院与心血管死亡复合终点(率比0.87,95%CI 0.75-1.01,P=0.06)。
- 沙库巴曲缬沙坦组心衰总住院690次 vs 缬沙坦组797次(率比0.85,95%CI 0.72-1.00),心血管死亡8.5% vs 8.9%(HR 0.95,95%CI 0.79-1.16)。
- 沙库巴曲缬沙坦组NYHA分级改善率15.0% vs 缬沙坦组12.6%(OR 1.45,95%CI 1.13-1.86),肾功能恶化1.4% vs 2.7%(HR 0.50,95%CI 0.33-0.77)。
- 沙库巴曲缬沙坦组低血压和血管性水肿发生率更高,高钾血症发生率更低。
- 预设亚组分析提示射血分数较低和女性患者可能从沙库巴曲缬沙坦获益。
适用人群与场景
- NYHA II-IV级心力衰竭患者,射血分数≥45%,利钠肽水平升高,并有结构性心脏病。
处置流程与药物剂量
- 沙库巴曲缬沙坦目标剂量为97mg沙库巴曲/103mg缬沙坦每日两次;缬沙坦目标剂量为160mg每日两次。
研究设计与关键结果
- PARAGON-HF随机对照试验纳入4822例患者,比较沙库巴曲缬沙坦与缬沙坦;主要复合终点(心衰总住院+心血管死亡)率比0.87(95%CI 0.75-1.01,P=0.06),未达统计学显著。
- 心血管死亡:沙库巴曲缬沙坦组8.5% vs 缬沙坦组8.9%(HR 0.95,95%CI 0.79-1.16);心衰总住院:690次 vs 797次(率比0.85,95%CI 0.72-1.00)。
- NYHA分级改善:沙库巴曲缬沙坦组15.0% vs 缬沙坦组12.6%(OR 1.45,95%CI 1.13-1.86);肾功能恶化:1.4% vs 2.7%(HR 0.50,95%CI 0.33-0.77)。
- 8个月时KCCQ临床总结评分平均变化沙库巴曲缬沙坦组高1.0分(95%CI 0.0-2.1)。
- 安全性:沙库巴曲缬沙坦组低血压和血管性水肿发生率更高,高钾血症发生率更低。
- 预设亚组分析提示射血分数较低和女性患者可能获益。
证据类型、等级与局限
- 证据类型:随机对照试验(PARAGON-HF)。
- 局限:原文未报告局限性。
对床旁实践的改变
- 对于射血分数≥45%的心衰患者,沙库巴曲缬沙坦未显著降低心衰总住院与心血管死亡复合终点,但可能改善NYHA分级和肾功能,需注意低血压和血管性水肿风险。
指南或共识出处
- PARAGON-HF试验(ClinicalTrials.gov NCT01920711),由诺华资助。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: The angiotensin receptor-neprilysin inhibitor sacubitril-valsartan led to a reduced risk of hospitalization for heart failure or death from cardiovascular causes among patients with heart failure and reduced ejection fraction. The effect of angiotensin receptor-neprilysin inhibition in patients with heart failure with preserved ejection fraction is unclear.
METHODS: We randomly assigned 4822 patients with New York Heart Association (NYHA) class II to IV heart failure, ejection fraction of 45% or higher, elevated level of natriuretic peptides, and structural heart disease to receive sacubitril-valsartan (target dose, 97 mg of sacubitril with 103 mg of valsartan twice daily) or valsartan (target dose, 160 mg twice daily). The primary outcome was a composite of total hospitalizations for heart failure and death from cardiovascular causes. Primary outcome components, secondary outcomes (including NYHA class change, worsening renal function, and change in Kansas City Cardiomyopathy Questionnaire [KCCQ] clinical summary score [scale, 0 to 100, with higher scores indicating fewer symptoms and physical limitations]), and safety were also assessed.
RESULTS: There were 894 primary events in 526 patients in the sacubitril-valsartan group and 1009 primary events in 557 patients in the valsartan group (rate ratio, 0.87; 95% confidence interval [CI], 0.75 to 1.01; P = 0.06). The incidence of death from cardiovascular causes was 8.5% in the sacubitril-valsartan group and 8.9% in the valsartan group (hazard ratio, 0.95; 95% CI, 0.79 to 1.16); there were 690 and 797 total hospitalizations for heart failure, respectively (rate ratio, 0.85; 95% CI, 0.72 to 1.00). NYHA class improved in 15.0% of the patients in the sacubitril-valsartan group and in 12.6% of those in the valsartan group (odds ratio, 1.45; 95% CI, 1.13 to 1.86); renal function worsened in 1.4% and 2.7%, respectively (hazard ratio, 0.50; 95% CI, 0.33 to 0.77). The mean change in the KCCQ clinical summary score at 8 months was 1.0 point (95% CI, 0.0 to 2.1) higher in the sacubitril-valsartan group. Patients in the sacubitril-valsartan group had a higher incidence of hypotension and angioedema and a lower incidence of hyperkalemia. Among 12 prespecified subgroups, there was suggestion of heterogeneity with possible benefit with sacubitril-valsartan in patients with lower ejection fraction and in women.
CONCLUSIONS: Sacubitril-valsartan did not result in a significantly lower rate of total hospitalizations for heart failure and death from cardiovascular causes among patients with heart failure and an ejection fraction of 45% or higher. (Funded by Novartis; PARAGON-HF ClinicalTrials.gov number, NCT01920711.).
参考来源
- Solomon SD, McMurray JJV, Anand IS, et al. Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction. N Engl J Med. 2019. PMID: 31475794. doi:10.1056/NEJMoa1908655
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。